BCAB
Companies
NASDAQ
BioAtla, Inc.
Health Care
$0.40
-$0.20 (-33.15%)
Price Chart
Overview
About BCAB
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Cap
$73.1M
Volume
270.1K
Avg. Volume
293.6K
P/E Ratio
-0.19061224
Dividend Yield
0.00%
Employees
66.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.30
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BCAB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$73.1M
Volume270.1K
P/E Ratio-0.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 28, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025